What a study run in another country has to satisfy here

Where the research in this market was done

Peptide product pages cite studies from everywhere. The published human record for several compounds here sits largely in Russian journals. Most of the registered trials that give one of the most heavily sold compounds here by vein were run in China, registered under the name Coenzyme I for Injection.

None of that makes a study wrong. Research is done in every country and good work is done in all of them. It does raise a question a reader is entitled to ask about any citation: what did this study have to satisfy before anyone here could rely on it?

There is a written answer. It is short, it is public, and almost nobody quotes it.

The rule, and the noun in its operative sentence

The regulation is titled "Foreign clinical studies not conducted under an IND." Its first sentence says that FDA will accept a well-designed and well-conducted foreign clinical study as support for an investigational new drug application, or for an application for marketing approval, if two conditions are met.

Read the noun before reading the conditions. This is a rule about what a sponsor or applicant may lean on in a submission to the agency. It is not a duty on a seller, it is not a standard a marketing page has to meet, and it says nothing about whether a study is good science.

That limit is the reason the rule is useful rather than the reason to ignore it. It is a regulator writing down, in plain terms, what it needs before it will rest a decision on work done outside its own system. A reader can ask the same questions without pretending they are legal requirements on anybody.

The two conditions

The first is that the study was conducted in accordance with good clinical practice, and the regulation defines that term for itself rather than pointing elsewhere. It is a standard for the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of clinical trials. The standard has to provide assurance that the data and reported results are credible and accurate, and that the rights, safety and well-being of trial subjects are protected.

The definition then names three specific things it includes. Review and approval by an independent ethics committee before the study starts. Continuing review by that committee while it runs. And obtaining and documenting the freely given informed consent of each subject before the study starts. A narrow exception exists for life-threatening situations where the committee finds in advance that consent is not feasible.

The second condition is one sentence long and it is the one most often forgotten. FDA has to be able to validate the data from the study through an onsite inspection, if the agency deems it necessary. A result nobody can go and check is not a result the agency will build on.

The sentence that stops this becoming a dismissal

The next paragraph is easy to skip and it changes the tone of the whole rule. Although FDA will not accept a study that fails those conditions as support for an application, the regulation says that FDA "will examine data from such a study."

Not accepted as support and not worth reading are different things. A study that cannot carry an application can still be informative, and the agency says so in its own text.

Anyone reporting a study as worthless because it was run abroad is claiming something this rule does not say. Anyone reporting it as adequate because it was published is claiming something the rule does not say either.

The eleven things a sponsor has to describe

If a sponsor does submit a foreign study, the rule lists eleven items it has to provide or cross-reference. The list reads like a set of questions a reader could ask of any cited study, which is what makes it worth knowing.

The investigator’s qualifications. A description of the research facilities. A detailed summary of the protocol and results, with case records or institutional records available on request. A description of how the sponsor monitored the study, and how investigators were trained to comply with good clinical practice.

Then the paperwork on the ethics committee: its name and address, a statement that it meets the regulation’s own definition, and a summary of its decision to approve the study or provide a favorable opinion. Records of the members and their qualifications have to be kept and produced on request.

Two more are pointed. One is a description of how informed consent was obtained. The other is a description of what incentives, if any, were provided to subjects to participate.

And where the study is intended to support effectiveness rather than safety, the sponsor has to show that it is adequate and well controlled under the agency’s own standard for that phrase.

The item that matters most on a product page

One entry on that list does more work than the rest for anyone reading a peptide listing. The sponsor has to describe the drug substance and the drug product used in the study. That description covers the components, the formulation, the specifications and, if available, the bioavailability of the specific product.

That is the question a citation almost never answers. A page cites a trial from another country and does not say whether the preparation studied resembles the preparation being sold. The same salt or free base, the same strength expression, the same route, the same excipients, the same specification: none of it is stated.

The regulator asks for that description because the answer is not obvious and the difference is not cosmetic. A study of a substance is not automatically a study of a product, and the rule is written on the assumption that the two can diverge.

When the foreign data is the only data

A second regulation covers the harder case, where an application rests on foreign clinical data alone. It sets three criteria, and the first is the one a reader intuitively cares about.

The foreign data have to be applicable to the United States population and to United States medical practice. The studies have to have been performed by clinical investigators of recognized competence. And the data have to be considered valid without an onsite inspection, or FDA has to be able to validate them by inspection or other appropriate means.

The regulation then closes the exit. Failure to meet any of those criteria results in the application not being approvable on the foreign data alone. It also says the agency will apply the policy in a flexible manner according to the nature of the drug and the data being considered.

That first criterion is worth carrying around. Whether a result travels is treated as a question about populations and medical practice, not as a formality about where the building was.

What this does and does not settle for a reader

Almost nothing in this market is inside an application at all. A compounded preparation is not an approved drug, and no sponsor has had to answer any of these questions about it. So the honest use of these rules is as a set of questions, not as a test anything has passed or failed.

The questions are still good ones. Was there an ethics committee, and did it review the study before it began. Was consent documented. Was the preparation studied described well enough to compare with the one on sale. Could anyone go and inspect the data. Were subjects paid, and does the paper say so.

A citation that answers those questions is doing more than decorating a claim. A citation that answers none of them may still describe real work, and it is not carrying as much weight as the page implies.

Two adjacent rules this is not

A separate filing rule governs foreign-language material submitted to the agency. Any part of a submission in another language must come with an English translation verified to be complete and accurate, together with the name, address and a brief statement of the translator’s qualifications. That rule is procedural, and it is why one compound sold here has a large Russian literature that a United States review did not weigh. The Semax article covers what that exclusion does and does not mean.

The other neighbor is the domestic sequence. Before a compound is given to a person in the United States for the first time, a specific chain of permissions has to exist, and that chain is described in its own article here. The rules on this page are what happens when the study was run outside that chain.

Both boundaries matter for the same reason. A rule that was written for one purpose stops being useful the moment it is stretched to another.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 312.120 — Foreign clinical studies not conducted under an IND, including the good clinical practice definition, the inspection condition, and the eleven supporting-information items — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
2. 21 CFR 314.106 — Foreign data, including the three criteria for approval based solely on foreign clinical data — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
3. 21 CFR 10.20 — Submission of documents to Dockets Management Staff, including the verified English translation requirement for foreign-language material — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026